Drug Trial Radar · NCT06493552
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
700
Planned (sponsor's estimate)
Start
Mar 15, 2025
Primary completion
Sep 2029
Study completion Aug 2034
Sponsor
- Lead sponsor
- Vasgene Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.
Conditions
- Muscle-Invasive Bladder Carcinoma
- Metastatic Urothelial Carcinoma
Interventions
SEphB4-HSADrug
A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.
PembrolizumabDrug
Antibody to human PD-1.
GemcitabineDrug
A chemotherapy drug used to treat various types of cancer.
CisplatinDrug
A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.
Enfortumab vedotinDrug
Nectin-4-directed antibody and microtubule inhibitor conjugate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improved pathological response (pCR) in sEphB4-HSA+Pembro vs. Standard of Care for MIBCTime frame: Through study completion, an average of 6 months
- Improved Overall Survival (OS) in sEphB4-HSA+Pembro vs. Standard of Care for MIBCTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
- Improved Radiographic Objective Response Rate (ORR) in sEphB4+Pembro vs. Control in mUCTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
- Non-inferior Overall Survival (OS) of sEphB4+Pembro vs. Control in mUCTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sarcoma Oncology Center
Santa Monica, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.